Volume 5, Issue 1, January 2019, Page: 5-9
Effect of Blood Transfusion on Platelet-Related Antibodies in ITP Patients
Li Meiling, The Third Affiliated Hospital of Guizhou Medical University, Duyun, China; Department of Hematology, Zhongshan Hospital Affiliated of Xiamen University, Xiamen, China
Li Long, The Third Affiliated Hospital of Guizhou Medical University, Duyun, China
Meng Fuxue, The Third Affiliated Hospital of Guizhou Medical University, Duyun, China
Received: Dec. 24, 2018;       Accepted: Jan. 22, 2019;       Published: Feb. 19, 2019
DOI: 10.11648/j.ijcems.20190501.12      View  108      Downloads  29
Abstract
Objective: To detect the expression of platclet associated immunoglobulin (PAIg) on the ITP patients’ platelet surface and study the effect and correlation of blood transfusion therapy on PAIg. Methods: The 173 patients confirmed as ITP selected form the outpatients and inpatients of the Department of Hematology and Rheumatology in the Third Affiliated Hospital of Guizhou Medical University, were divided into the blood transfusion group and the non-blood transfusion group, FCM fluorescence immunolabeling was used to measure expression quantity of PAIg, the positive expression rate and fluorescence intensity of PAIgG, PAIgM and PAIgA expressed on the platelet surface of ITP patients and the control group respectively. The softwave SPSS12.0 was applied to analyze the correlation. Results: (1) PAIgG (2.96 + 8.31) %, PAIgM (2.27 + 1.78) %, PAIgA (4.48 + 3.88) % in the non-transfusion group were significantly lower than those in the transfusion group (11.44 + 20.04) %, (9.72 + 15.24) %, (10.13 + 9.53) %, P<0.001. (2) The number of platelets in the non-transfusion group was significantly negatively correlated with PAIgM, r=-0.457, P<0.05. There was no significant correlation with PAIgG and PAIgA, all P values were >0.05. Conclusion: (1) It can increase platelet antibody after blood transfusion, and patients with ITP are more likely to produce platelet antibody after blood transfusion. (2) There is a certain degree of correlation between PAIg and blood transfusion in ITP patients.
Keywords
Idiopathic Thrombocytopenic Purpura, Platelet Related Antibodies, Blood Transfusion
To cite this article
Li Meiling, Li Long, Meng Fuxue, Effect of Blood Transfusion on Platelet-Related Antibodies in ITP Patients, International Journal of Clinical and Experimental Medical Sciences. Vol. 5, No. 1, 2019, pp. 5-9. doi: 10.11648/j.ijcems.20190501.12
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Lee ST, Kim JW, Kwon TG. Life-threating outcomes after dental implantation in patient with idiopathic thrombocytopenic purpura: a case report and review of literature. Maxillofac Plast Reconstr Surg. 2018, 40 (1): 39.
[2]
Mariotte E, Azoulay E, Galicier L, et al. French Reference Center for Thrombotic Microangiopathies: Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016, 3: 237–245.
[3]
Wu XF, Wang LJ, Sun L, et al. Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura. Exp Ther Med. 2017, 13 (2): 519–522.
[4]
Habe K, Wada H, Matsumoto T, et al. Presence of antiphospholipid antibodies as a risk factor for thrombotic events in patients with connective tissue diseases and idiopathic thrombocytopenic purpura. Intern Med. 2016, 55: 589–595.
[5]
McFarland J. Pathophysiology of platelet destruction in immune (idiopathic) thrombocytopenic purpura [J]. Blood Rev. 2002, 16 (1): 1-2.
[6]
Vautier M, GeorginLavialle S, Hermine O, et al. Efficiency and good tolerance of rituximab for idiopathic thrombocytopenic purpura revealing a 22q11 deletion syndrome. Rev Med Interne. 2016, 8: 15–16.
[7]
McKiddie FI, Watson HG, Graham D, et al. The impact of cell labelling technique on the retention of indium-labelled platelet imaging for idiopathic thrombocytopenic purpura. Nucl Med Commun. 2016, 37: 215–216.
[8]
Smalisz-Skrzypczyk K, Romiszewski M, Matysiak M, et al. The influence of primary cytomegalovirus or Epstein-Barr virus infection on the course of idiopathic thrombocytopenic purpura. Adv Exp Med Biol. 2016, 878: 83–88.
[9]
Park SH, Kim JY, Kim SK, et al. Regulatory T-cells in systemic lupus erythematosus-associated thrombocytopenia: a comparison with idiopathic thrombocytopenic purpura. Lupus. 2015, 24: e4.
[10]
Zhou H, Qiu JH, Wang T, et al. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. Blood, 2014, 124, 3316-3319.
[11]
Donald M, Arnold, ohn R. Nadia K, et al. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. Bri J Haematol, 2017, 178, 302-307.
[12]
Kuwana M, Kaburali J, Ieda Y, et al. Autoreactive T cells to platelet GP IIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Inverst. 1998, 102 (7): 1939-402.
[13]
Zhu XL, Zhang JM, Wang, QM, et al. Iminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Ann Hematol. 2018, 97: 641-654.
[14]
Zhang ZN, Chief editor. Criteria for diagnosis and efficacy of hematopathy [M]. 2nd edition. Beijing: Science Press. 1998, 279-85.
[15]
Wang LJ, The mechanism study of platelet activation and elevation in rheumatoid arthritis [D]. Shanxi Medical University. 2005.
[16]
Chen JF, Yang LH, Feng JJ, et al. Detection of thrombopoietin and platelet - related antibodies in patients with idiopathic thrombocytopenia purpurpura. Thrombosis and Hemostasis. 2009, 15 (3): 110-113.
[17]
Liu JZ. Diagnostic value of platelet specific antibody in idiopathic thrombocytopenic purpura. Journal of Guiyang Medical College, 2014, 39: 858-860, 864.
[18]
Harrington WJ, Minnich V, Hollingsworth JW, et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951, 38 (1): 1-10.
[19]
Miao XY. Study on the value of platelet-associated antibody level in the prognosis of idiopathic thrombocytopenic purpura. Northern Pharmacology. 2016, 8 (16): 125-126.
[20]
Xue L, Zhu WB, Wu JS, et al. Detection of platelet-associated antibodies and CD61 by flow cytometry in diagnosis of idiopathic thrombocytopenic purpura. Thrombosis and Hemostasis, 2011, 17 (1): 8-12.
[21]
Bao J. significance of detection of platelet specific autoantibodies and peripheral blood lymphocyte subsets in idiopathic thrombocytopenic purpura [D]. Anhui Medical University, 2007.
[22]
Liu MG, Wang F. Significance of flow cytometry detection of platelet-associated antibodies in diagnosis and treatment of idiopathic thrombocytopenic purpura. Modern Medicine & Health, 2015, 31 (5): 726-727.
[23]
Zhang YH, Yan WW, Yang TL, et al. Clinical analysis of 527 cases of idiopathic thrombocytopenic purpurpura. Chinese Journal of Hematology.1987, 6 (5): 265-266.
[24]
Zhang QH, Zhang J, Liu LN, et al. Detection and analysis of platelet antibody in patients with ineffective platelet transfusion after repeated transfusion. Clinical Transfusion and Test, 2015, 17 (5): 409-412.
[25]
Liu J, Sun XJ. Detection and analysis of platelet antibody in patients with ineffective platelet transfusion after multiple blood transfusions. Chinese Medical Journal, 2017, 6, 118.
Browse journals by subject